Blood safety and Zika by Centers for Disease Control and Prevention (U.S.) & Zika Action Plan Summit (2016 : Atlanta, GA)
www.cdc.gov/zika 






     
      
         
    
  
 
     
 
       
 
 
        
       
 
   
   
 
    
   
  
  
   
  
 
    
 
       
 
        
    
     
     
     
 
      
 
      
   
BLOOD SAFETY AND ZIKA
 
Ensuring safe and available blood requires coordination
The Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), and the National
Institutes of Health (NIH) work together to monitor the safety of the US blood supply. While the American Red Cross is
the largest supplier of blood in the United States, accounting for about 40% of collections, there are other blood
suppliers as well. Coordination between blood centers is crucial to ensure blood is safe and available.
Share how your jurisdiction will define “area of local transmission” for
Zika virus
•	 Blood collection centers need to know where there is local transmission of Zika virus so they can make sure they
are compliant with FDA Blood Donor Deferral Guidance
(http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/def 
ault.htm).
•	 Blood centers collecting in areas with local transmission of Zika virus have to import blood if it is not screened
using laboratory testing (not yet FDA approved) or subjected to pathogen reduction (only approved for platelets
and plasma).
•	 What is the appropriate geographic subdivision in reporting information from, and defining, an area of local 
transmission? For example, will reporting be accomplished at the zip code level or at the county or some other 
administrative level?
•	 Will identification of an area with local transmission where FDA Blood Donor Guidance needs to be applied be
determined according to the case characteristics?
o	 Single case
o	 Multiple linked cases
o	 Multiple unlinked cases
•	 Will identification be based on factors other than geographic region?
Identify a point person and engage in planning and communication with
partners




•	 Individual blood centers will decide if they will screen the blood they collect for Zika virus, once the test is
available. When an area has identified local Zika virus transmission, health departments need to ask blood
centers if they are screening blood for Zika virus or if they plan to outsource to replace donations in that area.
•	 Consider multiple forms of communication, such as
 Active, where state public health departments notify blood centers in real time about any new and
relevant matters.
 Passive, where the blood centers will monitor a website or other resource that you update periodically
or on a regular schedule.
•	 How will you approach the investigation of suspected transmission of Zika virus by blood transfusion and how
will you collaborate with blood centers?
www.cdc.gov/zika 





      
   
 
 





    
 
     
  
    
  
      
   
  
 
















   
   










   





   
 
    
 
  
Understanding FDA guidance for blood safety
You can find the full FDA recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk
of Transfusion-Transmission of Zika on FDA’s website:
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ 
UCM486360.pdf
For questions and answers about the FDA recommendations for Donor Screening, Deferral, and Product Management to
Reduce the Risk of Transfusion-Transmission of Zika, please visit
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ 
UCM490435.pdf





Defer donation for 4 weeks after symptoms consistent with
Zika for a:
o Donor with a history of Zika virus infection
o Donor who reports symptoms consistent with Zika 
within 2 weeks of leaving an area with active
transmission of Zika virus
o Donor who had sexual contact with a man who has
been diagnosed with Zika or traveled to or lived in an
area with active transmission of Zika virus in the past 3 
months
o Donor who has lived in or traveled to an area with
active transmission of Zika virus






dex.html to identify areas with
active transmission of Zika virus.
If local transmission is reported
in your state, contact your state 
and local health departments to
determine areas with active 
transmission of Zika virus.
Obtain Whole Blood and blood components for transfusion
from areas of the United States with no active transmission 
of Zika virus to fulfill orders.
You may:
o Collect and prepare platelets and plasma locally if you
implement pathogen reduction technology using an
FDA-approved pathogen reduction device as specified
in the Instructions for Use of the device.
o When available, collect blood components locally and
test blood donations with an FDA-licensed blood donor
screening test for Zika virus*.
o Only use locally collected blood components if blood
components from an area without active transmission
or pathogen-reduced blood components are not
available and the prescribing physician identifies an
urgent need for transfusion that outweighs the risk.
*An FDA-licensed blood donor screening test is not currently
available for Zika virus
Further background on CDC’s role in blood safety is available at http://www.cdc.gov/bloodsafety/
Investigation toolkit: http://www.cdc.gov/bloodsafety/tools/investigation-toolkit.html
